A 29-year-old woman with relapsed T-cell acute lymphoblastic leukemia presented with 4 months of progressive ataxia, weakness, and bowel/bladder incontinence. Symptoms started after completing 2 cycles of nelarabine. Examination revealed paraplegia and complete sensory loss from mid-chest down, loss of vibration and joint position in upper limbs, areflexia, and bilateral Babinski signs. EMG showed fibrillation potentials with no activated motor units in lower limbs. Laboratory workup, including paraneoplastic autoantibody panel, CSF analysis, vitamin B12, methylmalonic acid, and copper levels, was unremarkable. Spine MRI findings were consistent with nelarabine-induced subacute combined degeneration, including previously unreported lateral column involvement and cord enhancement (figure).1,2 The unremarkable CSF, MRI findings (tractopathy), and subacute course made alternative etiologies such as infection, infiltrative leukemia, ischemia, or cord hemorrhage less likely. The patient was treated conservatively and started to spontaneously improve. She then underwent allogenic stem cell transplantation. Three months later, she regained movement against gravity in all lower extremity muscles. However, she remained severely ataxic, requiring the use of a wheelchair. Repeat EMG showed reinnervation in most lower-limb muscles and less frequent fibrillation potentials.
MRI of the cervical (A, C, and E) and thoracic (B and D) spine. Sagittal T2-weighted (A), sagittal short tau inversion recovery (B), axial T2-weighted (C–D), and axial T1-weighted postcontrast (E) images demonstrate extensive T2 hyperintensity of the dorsal (A–D, arrows) and lateral columns (D, dashed arrows), with dorsal column enhancement at the cervicomedullary junction (E, arrowhead).
Study Funding
No targeted funding reported.
Disclosure
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
Appendix Authors
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- © 2020 American Academy of Neurology
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.